SM
ARQT icon

SG3 Management’s Arcutis Biotherapeutics ARQT Stock Holding History

SG3 Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,500
Closed -$479K – 294
2022
Q2 		$479K Buy
22,500
+5,500
+32% +$113K 0.06% 214
2022
Q1 		$327K Buy
+17,000
New +$288K 0.01% 680

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SG3 Management's ARQT Position: Q3 2022 in Review

SG3 Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2022, closing a stake of 22,500 shares — an estimated $479K sold.

SG3 Management first reported a position in ARQT in Q1 2022 and held it in 2 quarters. The position peaked at $479K in Q2 2022. 139 funds tracked by Wall St. Rank hold ARQT as of Q3 2022.

  • SG3 Management reported no remaining Arcutis Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • SG3 Management sold 22,500 Arcutis Biotherapeutics shares in Q3 2022, an estimated $479K.
  • SG3 Management first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 2 quarters.
  • SG3 Management's Arcutis Biotherapeutics position peaked at $479K in Q2 2022.
  • 139 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.